Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 315

1.

Activation of CHK1 in Supporting Cells Indirectly Promotes Hair Cell Survival.

Jadali A, Ying YM, Kwan KY.

Front Cell Neurosci. 2017 May 18;11:137. doi: 10.3389/fncel.2017.00137. eCollection 2017.

2.

The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy.

Iwata T, Uchino T, Koyama A, Johmura Y, Koyama K, Saito T, Ishiguro S, Arikawa T, Komatsu S, Miyachi M, Sano T, Nakanishi M, Shimada M.

PLoS One. 2017 May 30;12(5):e0178221. doi: 10.1371/journal.pone.0178221. eCollection 2017.

3.

The G2 checkpoint-a node-based molecular switch.

de Gooijer MC, van den Top A, Bockaj I, Beijnen JH, Würdinger T, van Tellingen O.

FEBS Open Bio. 2017 Mar 4;7(4):439-455. doi: 10.1002/2211-5463.12206. eCollection 2017 Apr.

4.

Microvesicles Contribute to the Bystander Effect of DNA Damage.

Lin X, Wei F, Major P, Al-Nedawi K, Al Saleh HA, Tang D.

Int J Mol Sci. 2017 Apr 7;18(4). pii: E788. doi: 10.3390/ijms18040788.

5.

Impact of Age and Insulin-Like Growth Factor-1 on DNA Damage Responses in UV-Irradiated Human Skin.

Kemp MG, Spandau DF, Travers JB.

Molecules. 2017 Feb 26;22(3). pii: E356. doi: 10.3390/molecules22030356. Review.

6.

The Intra-S Checkpoint Responses to DNA Damage.

Iyer DR, Rhind N.

Genes (Basel). 2017 Feb 17;8(2). pii: E74. doi: 10.3390/genes8020074. Review.

7.

Cell cycle proteins as promising targets in cancer therapy.

Otto T, Sicinski P.

Nat Rev Cancer. 2017 Jan 27;17(2):93-115. doi: 10.1038/nrc.2016.138. Review.

PMID:
28127048
8.

Lack of Casein Kinase 1 Delta Promotes Genomic Instability - The Accumulation of DNA Damage and Down-Regulation of Checkpoint Kinase 1.

Greer YE, Gao B, Yang Y, Nussenzweig A, Rubin JS.

PLoS One. 2017 Jan 26;12(1):e0170903. doi: 10.1371/journal.pone.0170903. eCollection 2017.

9.

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models.

Kim H, George E, Ragland R, Rafial S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown E, Simpkins F.

Clin Cancer Res. 2017 Jun 15;23(12):3097-3108. doi: 10.1158/1078-0432.CCR-16-2273. Epub 2016 Dec 19.

PMID:
27993965
10.

Induction of a Cellular DNA Damage Response by Porcine Circovirus Type 2 Facilitates Viral Replication and Mediates Apoptotic Responses.

Wei L, Zhu S, Wang J, Quan R, Yan X, Li Z, Hou L, Wang N, Yang Y, Jiang H, Liu J.

Sci Rep. 2016 Dec 16;6:39444. doi: 10.1038/srep39444.

11.

Insulin-like Growth Factor 1 Receptor Signaling Is Required for Optimal ATR-CHK1 Kinase Signaling in Ultraviolet B (UVB)-irradiated Human Keratinocytes.

Kemp MG, Spandau DF, Simman R, Travers JB.

J Biol Chem. 2017 Jan 27;292(4):1231-1239. doi: 10.1074/jbc.M116.765883. Epub 2016 Dec 15.

PMID:
27979966
12.

DNA Damage Response and Autophagy: A Meaningful Partnership.

Eliopoulos AG, Havaki S, Gorgoulis VG.

Front Genet. 2016 Nov 21;7:204. eCollection 2016. Review.

13.

Recovery from the DNA Replication Checkpoint.

Chaudhury I, Koepp DM.

Genes (Basel). 2016 Oct 28;7(11). pii: E94. Review.

14.

Prospects for the Use of ATR Inhibitors to Treat Cancer.

Wagner JM, Kaufmann SH.

Pharmaceuticals (Basel). 2010 Apr 28;3(5):1311-1334. Review.

15.

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.

Zemanova J, Hylse O, Collakova J, Vesely P, Oltova A, Borsky M, Zaprazna K, Kasparkova M, Janovska P, Verner J, Kohoutek J, Dzimkova M, Bryja V, Jaskova Z, Brychtova Y, Paruch K, Trbusek M.

Oncotarget. 2016 Sep 20;7(38):62091-62106. doi: 10.18632/oncotarget.11388.

16.

Activation of DNA damage repair pathways by murine polyomavirus.

Heiser K, Nicholas C, Garcea RL.

Virology. 2016 Oct;497:346-56. doi: 10.1016/j.virol.2016.07.028. Epub 2016 Aug 16.

17.

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.

Ghelli Luserna Di Rorà A, Iacobucci I, Imbrogno E, Papayannidis C, Derenzini E, Ferrari A, Guadagnuolo V, Robustelli V, Parisi S, Sartor C, Abbenante MC, Paolini S, Martinelli G.

Oncotarget. 2016 Aug 16;7(33):53377-53391. doi: 10.18632/oncotarget.10535.

18.

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.

Manic G, Obrist F, Sistigu A, Vitale I.

Mol Cell Oncol. 2015 Feb 23;2(4):e1012976. doi: 10.1080/23723556.2015.1012976. eCollection 2015 Oct-Dec. Review.

19.

Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.

Zhang Y, Lai J, Du Z, Gao J, Yang S, Gorityala S, Xiong X, Deng O, Ma Z, Yan C, Susana G, Xu Y, Zhang J.

Oncotarget. 2016 Jun 7;7(23):34688-702. doi: 10.18632/oncotarget.9156.

20.

Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.

Zhao J, Niu X, Li X, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Ge Y.

Oncotarget. 2016 Jun 7;7(23):34785-99. doi: 10.18632/oncotarget.9185.

Supplemental Content

Support Center